Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.chom.2021.02.020 http://scihub22266oqcxt.onion/10.1016/j.chom.2021.02.020 33789086!7919536!33789086     free     free     free       Cell+Host+Microbe 2021 ; 29 (4): 508-515 Nephropedia Template TP {{tp|p=33789086|t=2021. The variant gambit: COVID-19 s next move |pdf=|usr=}}{{33789086}} gab.com Text The variant gambit: COVID-19 s next move JO: Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33789086 #FOAvip More than a year after its emergence, COVID-19, the disease caused by SARS-CoV-2, continues to plague the world and dominate our daily lives. Even with the development of effective vaccines, this coronavirus pandemic continues to cause a fervor with the identification of major new variants hailing from the United Kingdom, South Africa, Brazil, and California. Coupled with worries over a distinct mink strain that has caused human infections and potential for further mutations, SARS-CoV-2 variants bring concerns for increased spread and escape from both vaccine and natural infection immunity. Here, we outline factors driving SARS-CoV-2 variant evolution, explore the potential impact of specific mutations, examine the risk of further mutations, and consider the experimental studies needed to understand the threat these variants pose. In this review, Plante et al. examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California). They focus on what factors contribute to variant emergence, mutations in and outside the spike protein, and studies needed to understand the impact of variants on infection, transmission, and vaccine efficacy. Twit Text FOAVip The variant gambit: COVID-19 s next move ????Cell Host Microbe http://www.kidney.de/pget.php?&tw=1&pmid=33789086 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33789086 #FOAvip English Wikipedia <ref>{{Cite pmid|33789086}}</ref> The variant gambit: COVID-19 s next move #MMPMID33789086 Plante JA; Mitchell BM; Plante KS; Debbink K; Weaver SC; Menachery VD Cell Host Microbe 2021[Apr]; 29 (4): 508-515 PMID33789086show ga More than a year after its emergence, COVID-19, the disease caused by SARS-CoV-2, continues to plague the world and dominate our daily lives. Even with the development of effective vaccines, this coronavirus pandemic continues to cause a fervor with the identification of major new variants hailing from the United Kingdom, South Africa, Brazil, and California. Coupled with worries over a distinct mink strain that has caused human infections and potential for further mutations, SARS-CoV-2 variants bring concerns for increased spread and escape from both vaccine and natural infection immunity. Here, we outline factors driving SARS-CoV-2 variant evolution, explore the potential impact of specific mutations, examine the risk of further mutations, and consider the experimental studies needed to understand the threat these variants pose. In this review, Plante et al. examine SARS-CoV-2 variants including B.1.1.7 (UK), B.1.351 (RSA), P.1 (Brazil), and B.1.429 (California). They focus on what factors contribute to variant emergence, mutations in and outside the spike protein, and studies needed to understand the impact of variants on infection, transmission, and vaccine efficacy. |*Mutation[MESH] |Humans[MESH] |SARS-CoV-2/*genetics/immunology[MESH]The variant gambit: COVID-19 s next move (epmc).pdf DeepDyve Pubget Overpricing